ArticleFrontiers in oncology2021

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia.

Mark Wunderlich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.